EUVIMEDEUVIMED entdecken
Systematische Übersicht

Naltrexone for Ocular Applications: A Mini-Update on Nanocarriers, Patents, and Evidence Analysis

Bakr Ahmed iD, Gajanand Sharma iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00622 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Bakr Ahmed und 1 weiteren Autor:innen. Beteiligte Einrichtung: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, Punjab 160014, India. Hauptthemen laut MEDLINE: Naltrexone, Nanoparticles, Drug Carriers, Eye Diseases. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delivering drugs to the eye remains a significant challenge due to complex anatomical and physiological barriers. Naltrexone (NTX), an opioid receptor antagonist with anti-inflammatory and immunomodulatory properties, has emerged as a promising candidate for ocular therapy. This systematic review examines NTX-based ocular delivery systems advancements, focusing on nanoformulations such as niosomes, hydrogels, in situ gelling films, and polymeric matrices. A literature search (2006-2024) across PubMed, Google Scholar, and Web of Science identified 14 original studies and 4 patents. These formulations improved NTX's solubility, precorneal retention, corneal penetration, sustained release, and photostability. Using the GRADE framework, we found high certainty of evidence for enhanced solubility, retention, sustained release, and safety. Moderate certainty supported NTX's efficacy in diabetic keratopathy, tear production, corneal healing, and ocular bioavailability. Overall, nanoformulated NTX shows strong potential for managing ocular conditions, highlighting the role of advanced delivery systems in improving therapeutic outcomes while minimizing side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexoneNanoparticlesDrug CarriersEye DiseasesNarcotic AntagonistsHumansAnimalsDrug Delivery SystemsPatents as TopicAdministration, Ophthalmic

Stichwörter der Autor:innen

corneal penetrationcorneal wound healingdry eye syndromenanoformulationsocular inflammation

Substanzen

NaltrexoneDrug CarriersNarcotic Antagonists

Autor:innen und Institutionen

  • University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, Punjab 160014, India.

ORCID-Profile: Bakr Ahmed, Gajanand Sharma

Zitieren

APA

Ahmed, B., & Sharma, G. (2025). Naltrexone for Ocular Applications: A Mini-Update on Nanocarriers, Patents, and Evidence Analysis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00622

Vancouver

Ahmed B, Sharma G. Naltrexone for Ocular Applications: A Mini-Update on Nanocarriers, Patents, and Evidence Analysis. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00622

BibTeX
@article{Ahmed2025,
  author = {Ahmed, Bakr and Sharma, Gajanand},
  title = {Naltrexone for Ocular Applications: A Mini-Update on Nanocarriers, Patents, and Evidence Analysis},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00622}
}
Kostenlos starten →